These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9543464)

  • 1. Metrifonate: overview of safety and efficacy.
    Cummings JL
    Pharmacotherapy; 1998; 18(2 Pt 2):43-6; discussion 79-82. PubMed ID: 9543464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacology of metrifonate.
    Jann MW
    Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating response to metrifonate.
    Tariot PN
    J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.
    Liu L; Ikonen S; Heikkinen T; Tapiola T; van Groen T; Tanila H
    Exp Neurol; 2002 Feb; 173(2):196-204. PubMed ID: 11822883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
    McKeith IG
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metrifonate: update on a new antidementia agent.
    Ringman JM; Cummings JL
    J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
    Schmidt BH; Heinig R
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metrifonate for Alzheimer's disease patients.
    Schneider LS
    J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
    [No Abstract]   [Full Text] [Related]  

  • 10. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alzheimer disease. Irreversible AChE inhibition with metrifonate].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1998 Aug; 21(8):250. PubMed ID: 9758555
    [No Abstract]   [Full Text] [Related]  

  • 12. Metrifonate: a new agent for the treatment of Alzheimer's disease.
    Williams BR
    Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
    Knopman DS
    Neurology; 1998 May; 50(5):1203-5. PubMed ID: 9595961
    [No Abstract]   [Full Text] [Related]  

  • 14. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
    Piecoro LT; Wermeling DP; Schmitt FA; Ashford JW
    Pharmacotherapy; 1998; 18(5):1129-32. PubMed ID: 9758325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
    Cummings JL; Nadel A; Masterman D; Cyrus PA
    J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
    Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
    Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
    Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.